Amgen Inc. Reaches $71 Million Settlement in Enbrel and Aranesp Marketing Case

Recent Events Involving Police May Lead to High Settlements in Personal Injury Suits
September 8, 2015
Families of Two Doctoral Students Receive $8.6 Million Verdict in Wrongful Death Suit
September 11, 2015

Helen Jones
Executive Vice President 

In August, pharmaceutical powerhouse, Amgen Inc., reached a $71 million settlement with the 48 continental United States and the District of Columbia over claims arising from the company’s marketing practices of their popular drugs, Enbrel and Aranesp. Enbrel, a medicine to treat moderate to severe plaque psoriasis, and Aranesp, used to treat only certain types of anemia, were the center of marketing claims against Amgen when the company marketed the drugs for uses which were not FDA approved. The company was wrongfully marketing Enbrel for the treatment of mild plaque psoriasis, and Aranesp for treating anemia caused by cancer.

Plaintiff Support offers a variety of settlement funding services to help plaintiffs and attorneys during and after a personal injury case. Learn more about how we can help you.

Comments are closed.